Becton Dickinson and Co

Aktienanalyse zu Becton Dickinson and Co (BDX)

$195.160

+0.137 (+0.07%)Zum Schluss

Loading chart…
Hoch
196.880
Eröffnung
194.220
Volumengewichteter Durchschnittskurs
195.28
Volumen
1.74M
Marktkap.
66.74B
Tief
193.800
Umsatz
339.88M
EV/EBITDA, TTM
12.82

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences.

www.bd.com

KI-Analyse of Becton Dickinson and Co (BDX)

Kaufen

Becton Dickinson (BDX) is a good buy right now, with a current price of $198.91 and a forward P/E ratio of 13.72, indicating potential for growth compared to its earnings. The stock has shown a 5-day change of +3.73%, reflecting positive momentum. However, the RSI is at 75.30, suggesting it may be overbought in the short term, which is a risk to consider.

Analystenbewertungen (15)

-1.29% Abwärtspotenzial
Kaufen
10 Kaufen
5 Halten
0 Verkaufen
Aktuell: 195.16
Tief
157.00
Durchschnitt
192.64
Hoch
232.00

Barclays

2026-10-07

Kursziel

$165

Untergewichten

BofA

2026-08-31

Kursziel

$200

Neutral

RBC Capital

2026-08-13

Kursziel

$190

Sector Perform

Citi

2026-08-13

Kursziel

$208

Kaufen

RBC Capital

2026-08-07

Kursziel

$180

Sector Perform

Bewertungskennzahlen

Das aktuelle erwartete KGV von Becton Dickinson and Co (BDX) beträgt 14.95, verglichen mit dem 5-Jahres-Durchschnitt von 17.14.

Erwartetes KGV

Fair bewertet
5J-Durchschnitt P/E
17.14
Aktuelles P/E
14.95
Überbewertet
20.80
Unterbewertet
13.48

Erwartetes EV/EBITDA

Fair bewertet
5J-Durchschnitt EV/EBITDA
14.08
Aktuelles EV/EBITDA
12.82
Überbewertet
16.37
Unterbewertet
11.80

Erwartetes KUV

Fair bewertet
5J-Durchschnitt P/S
3.17
Aktuelles P/S
2.71
Überbewertet
3.75
Unterbewertet
2.58

Alphio-AI-Kursszenarien für BDX

Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.

B

Bullisch

Bullisch · 25%BDX

$193.53

Szenariopreis

B

Basis

Basis · 50%BDX

$172.62

Szenariopreis

B

Bärisch

Bärisch · 25%BDX

$171.68

Szenariopreis

Whales, die BDX halten

L

LGPS Central Limited

+ HältBDX

+6.25%

3-Monats-Rendite

B

Beutel Goodman & Company Ltd.

+ HältBDX

+4.78%

3-Monats-Rendite

J

John W. Bristol & Co., Inc.

+ HältBDX

+4.41%

3-Monats-Rendite

V

Veritas Asset Management LLP

+ HältBDX

+3.14%

3-Monats-Rendite

T

The Bryn Mawr Trust Company

+ HältBDX

+2.75%

3-Monats-Rendite

I

Invenomic Capital Management LP

+ HältBDX

+2.71%

3-Monats-Rendite

Event-Zeitleiste

2026-10-28 (ET)

09:53:00

Becton Dickinson Launches Liverty TIPS Stent Graft

2026-10-07 (ET)

08:30:00

BD Reports Positive Nine-Month Results for Revello Vascular Covered Stent

2026-10-06 (ET)

07:00:00

Becton Dickinson Partners with U.S. Government for $19B Manufacturing Expansion

2026-09-21 (ET)

17:00:00

Becton, Dickinson Appoints Arthur Hu as Chief Information Officer

2026-08-12 (ET)

07:00:00

Becton Dickinson Completes Enrollment in PREVENT Clinical Trial

News

BDX FAQ – beantwortet von Alphio AI

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. It operates through five segments: BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional, and BD Life Sciences. BD Medical Essentials segment includes medication delivery solutions and specimen management. BD Connected Care segment includes medication management solutions and advanced patient monitoring. BD Interventional segment includes urology and critical care, peripheral intervention and surgery. Its Life Sciences segment includes diagnostic solutions and biosciences. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Becton Dickinson (BDX) is a good buy right now, with a current price of $198.91 and a forward P/E ratio of 13.72, indicating potential for growth compared to its earnings. The stock has shown a 5-day change of +3.73%, reflecting positive momentum. However, the RSI is at 75.30, suggesting it may be overbought in the short term, which is a risk to consider.

15 analysts cover BDX: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 192.64.

Community

Mehr ↗
range_bonder16.9.2026

Beldex @BeldexCoin recently published two research pieces, and I think they are interesting to look at together. One is about age verification: you only need to prove you are over 18, without handing over your birthday, identity, and nationality all at once. At the same time, it checks that the credential signature is real, that the age is actually derived from that birthday, that the same number is locked in the commitment, and that this number is not below 18. In the end, the other party only gets one result: you meet the age requirement. This is still research for now. Beldex Research Labs is next trying Bulletproof to make the proof smaller and push verification cost down further. It has not yet become a ready feature in BChat or the wallet. The other is VRF consensus. Beldex's current PoS already has a layer of random validator selection. What VRF aims to add is verifiable randomness: everyone can later verify whether the result of who got selected followed the rules, while before the draw it is harder to predict in advance who the next batch will be. The team currently places the VRF-based PoS hardfork in Q1 2027. This is also a later upgrade, not something already fully switched over on mainnet now. One is dealing with how much identity information should be exposed, and the other is dealing with how randomness in consensus should be proven. These two research lines at Beldex are actually quite consistent in direction: provide enough information, and avoid exposing extra information as much as possible.

Mehr anzeigen
Registriere dich oder melde dich an, um mitzudiskutieren

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln